01 April 2008
Rosiglitazone in the prevention of diabetes and cardiovascular disease: Dream or reality?
Tomas Stulc, Richard CeskaMed Sci Monit 2008; 14(4): RA45-47 :: ID: 850308
Abstract
Results of the recently published DREAM trial seemingly demonstrate that the PPAR-γ agonist rosiglitazone is effective in the prevention of diabetes. However, a more detailed inspection of the trial shows that rosiglitazone is masking rather than preventing the progression to diabetes. This questionable effect was achieved at the price of unnecessarily treating approximately five subjects who would remain nondiabetic anyway for each case of “prevented” diabetes, with all the associated costs and risks. The trial also raises the unexpected possibility that rosiglitazone may substantially increase the risk of cardiovascular events, which would be particularly harmful in the high-risk patients with diabetes. This possibility is further supported by the results of several recent meta-analyses. In addition, these serious safety concerns should be carefully weighed against the weak evidence of benefit which, so far, is limited to laboratory endpoints. Therefore, rather than extending the use of rosiglitazone to the prevention of diabetes, the DREAM trial calls in question the safety of this drug as such in any patient and casts some doubt upon the whole class of PPAR-γ agonists. With respect to its wide use in clinical practice, the potential risks of rosiglitazone warrant careful investigation and, in the meantime, this drug should be used with caution.
Keywords: Diabetes Mellitus - prevention & control, Cardiovascular Diseases - prevention & control, PPAR gamma - metabolism, Risk Factors, Thiazolidinediones - pharmacology
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952